Bio-Thera Announces BLA Acceptance of Humira's Biosimilar (BAT1406) by China National Drug Administration (CNDA)
Shots:
- This BLA is for the treatment of RA- PsA- AS- CD- UC- chronic psoriasis- HS- and JIA
- The clinical study included (PK/PD) and Ph III trials in ankylosing spondylitis showing its safety- efficacy and quality
- Bio-Thera is developing 7 biosimilars including BAT1406- with Avastin biosimilar currently being assessed in a global Ph III trial
Ref: Businesswire | Image: LinkedIn
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com